| Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy (NCT04292080) | Assistance Publique - Hôpitaux de Paris | 2022-02-07 |
| Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program (NCT05066685) | Novartis Pharmaceuticals | 2020-08-11 |
| Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) (NCT05146687) | Novartis Pharmaceuticals | 2020-07-15 |
| Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study) (NCT05082415) | Novartis Pharmaceuticals | 2020-06-03 |
| Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab (NCT05037396) | Novartis Pharmaceuticals | 2020-03-05 |
| Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context (NCT03577041) | Centre Hospitalier Universitaire, Amiens | 2020-01-29 |
| Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place (NCT03690505) | University Hospital, Limoges | 2019-03-12 |
| Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention (NCT03859245) | Bristlecone Health, Inc. | 2019-02-23 |
| Development of Novel Clinical Endpoints in Intermediate AMD (NCT03349801) | Frank G. Holz | 2018-03-26 |
| Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada (NCT02585401) | Bayer | 2016-02-18 |
| Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (NCT02611778) | Bioeq GmbH | 2015-12-19 |
| Production of iPSC Derived RPE Cells for Transplantation in AMD (NCT02464956) | Moorfields Eye Hospital NHS Foundation Trust | 2015-12-01 |
| Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration (NCT02398500) | Alcon Research | 2015-07-22 |
| Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device (NCT02445313) | Doheny Image Reading Center | 2015-06-01 |
| X-82 to Treat Age-related Macular Degeneration (NCT02348359) | Tyrogenex | 2015-03-16 |
| Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort (NCT07424235) | IRCCS Ospedale San Raffaele | 2015-01-01 |
| Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (NCT02022540) | PanOptica, Inc. | 2014-02-01 |
| Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (NCT02121353) | Pfenex, Inc | 2013-11-01 |
| Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) (NCT01722045) | Regeneron Pharmaceuticals | 2012-11-01 |
| Intervention Trial in Early Age-related Macular Degeneration (NCT01694680) | Newtricious R&D BV | 2012-10-01 |
| A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) (NCT01542866) | Novartis Pharmaceuticals | 2011-01-11 |
| Intravitreal Injection Anesthesia - Comparison of Different Topical Agents (NCT01224847) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2009-10-01 |
| Genetics and Markers of Degenerative and Inflammatory Eye Diseases (NCT00647439) | National Eye Institute (NEI) | 2008-03-27 |
| A Study Of Early Markers Of Choroidal Neovascularization (NCT00902785) | Pfizer | 2008-03-01 |
| An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD (NCT00327470) | Pfizer | 2006-07-01 |
| A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD (NCT00354445) | Eyetech Pharmaceuticals | 2006-06-01 |